Catalyst Pharma CEO Richard Daly gives an overview of the company's three commercial products, and discusses the 'buy to build' model
- blonca9
- Sep 8, 2025
- 1 min read
Updated: Sep 9, 2025
He highlights the market penetration of FIRDAPSE, the differentiation he believes AGAMREE represents in the DMD space, and FYCOMPA. Plus, the company's financial strength.
Coverage brought to you by:















.png)

